We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

WuXi Biologics (Cayman) Inc., an investment holding company, provides end-to-end solutions and services for biologics discovery, development, and manufacturing for biologics industry in the People ...

WuXi Biologics (Cayman) Inc., an investment holding company, provides end-to-end solutions and services for biologics discovery, development, and manufacturing for biologics industry in the People ...

Dublin, May 22, 2025 (GLOBE NEWSWIRE) -- The "Biologics CDMO Market - A Global and Regional Analysis: Focus on Cell Type, Indication, Molecule Type, and Region - Analysis and Forecast, 2025-2035 ...

Wuxi Biologics (Cayman) Inc. + Watchlist Alert WXIBF US Closed Last Updated: Jun 17, 2025 11:05 a.m. EDT Delayed quote $ 3.2500 0.0400 1.25% Previous Close $3.2100 Toggle Chart Options Advanced ...

Under the deal, CRISPR can pick up to two more siRNA targets. 5. WuXi Biologics slims down again, handing off German plant to CDMO Terumo for $167M WuXi Biologics is shedding another facility ...

SEOUL ― South Korean drugmaker Samsung BioLogics said on Thursday it plans to separate the company into contract manufacturing and development companies to help allay customer concerns about conflicts ...

In a bid to allay conflict-of-interest concerns, Korean manufacturing giant Samsung Biologics is decoupling from its biosimilars development unit. Starting later this year, Samsung Bio will devote ...

Samsung Biologics announced on the 22nd that it will establish 'Samsung Bioepis Holdings' through a simple spin-off method. The plan is to completely separate the contract development and ...